Bacterial lipoproteins differentially regulate human primary and memory CD4+ T and B cell responses to pneumococcal protein antigens through toll-like receptor 2

Journal of Infectious Diseases

Volumn 201, Issue 11, 2010, Pages 1753-1763

  Zhang, Qibo ^a,d   Bagrade, Linda ^b   Clarke, Ed ^a   Paton, James C ^e   Nunez, Desmond A ^c   Finn, Adam ^a,b  

^a Departments of Cellular and Molecular Medicine   (United Kingdom)

^b Clinical Science at South Bristol   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM LIPOPROTEIN; CD28 ANTIGEN; CHOLINE BINDING PROTEIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PNEUMOCOCCAL SURFACE PROTECTIVE ANTIGEN A; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADENOID; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; DOWN REGULATION; HUMAN; MEMORY CELL; MEMORY T LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

EID: 77951923629     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652495     Document Type: Article

References (40)

1. Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999; 285(5428):732-736.
2. Hirschfeld M, Kirschning CJ, Schwandner R, et al. Cutting edge; inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999; 163(5);2382-2386.
3. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge; role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169(1);10-14.
4. Bessler WG, Cox M, Lex A, et al. Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes. J Immunol 1985; 135(3);1900-1905.
5. Sieling PA, Chung W, Duong BT, et al. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 2003; 170(1);194-200.
6. Ghielmetti M, Zwicker M, Ghielmetti T, et al. Synthetic bacterial lipopeptide analogs facilitate naive CD4+ T cell differentiation and enhance antigen-specific HLA-II-restricted responses. Eur J Immunol 2005; 35(8);2434-2442.
7. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptidebased therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95(1);341-349.
8. Nardin EH, Calvo-Calle JM, Oliveira GA, et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001; 166(1);481-489.
9. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397(6716);263-266.
10. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergeninduced airway hyperreactivity. Nature Medicine 2002; 8(9):1024-1032.
11. Kohyama M, Sugahara D, Sugiyama S, et al. Inducible costimulatordependent IL-10 production by regulatory T cells specific for selfantigen. Proc Natl Acad Sci USA 2004; 101(12):4192-11197
12. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 1996;64(4);1272-1283.
13. Kurono Y, Yamamoto M, Fujihashi K, et al. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 1999; 180(1);122-132.
14. Jakobsen H, Jonsdottir I, Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria-new potentials for conjugate vaccines?. Scand J Immunol 2003;58(2);119-128.
15. Jakobsen H, Bjarnarson S, Del GG, et al. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 2002;70(3);1443-1452.
16. Rharbaoui F, Drabner B, Borsutzky S, et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 2002;32(10);2857-2865.
17. Baier W, Masihi N, Huber M, et al. Lipopeptides as immunoadjuvants and immunostimulants in mucosal immunization. Immunobiology 2000;201:391-1105
18. Zhang Q, Choo S, Finn A. Immune responses to novel pneumococcal proteins (Pneumolysin, PspA, PsaA and CbpA) in adenoidal B cells from children. Infect Immun 2002;70(10);5363-5369.
19. Zhang Q, Bernatoniene J, Bagrade L, et al. Serum and mucosal antibody responses to pneumococcal protein antigens in children; relationships with carriage status. Eur J Immunol 2006; 36:46-57. (Pubitemid 43116391)
20. Malley R, Stack AM, Ferretti ML, Thompson CM, Saladino RA. Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats. J Infect Dis 1998; 178(3): 878-8782.
21. Kadioglu A, Coward W, Colston MJ, Hewitt CR, Andrew PW. CD4T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect Immun 2004;72(5):2689-2697.
22. McCool TL, Weiser JN. Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization. Infect Immun 2004;72(10):5807-5813.
23. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4 T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005; 102:4848-4853. (Pubitemid 40471542)
24. Zhang Q, Bernatoniene J, Bagrade L, et al. Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. J Infect Dis 2007; 195(15):1194-1202.
25. Rosenow C, Ryan P, Weiser JN, et al. Contribution of novel cholinebinding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997;25:819-829.
26. Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun 2001;69(10):5997-6003.
27. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000;68(5):3028-3033.
28. Zan-Bar I, Vitetta ES, Assisi F, et al. The relationship between surface immunoglobulin isotype and immune function of murine B lymphocytes. III. Expression of a single predominant isotype on primed and unprimed B cells. J Exp Med 1978; 147(5):1374-1394.
29. Zhang Q, Bernatoniene J, Bagrade L, et al. Regulation of mucosal antibody production to pneumococcal protein antigens by T-cell derived IFNg and IL-10 in children. Infect Immun 2006; 74(8):4735-4743.
30. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
31. Liu H, Komai-Koma M, Xu D, et al. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 2006; 103(18):7048-7053.
32. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389(6652):737-1472
33. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192(9):1213-1222.
34. Lohning M, Hutloff A, Kallinich T, et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 2003; 197(2): 181-193. (Pubitemid 36152313)
35. McAdam AJ, Schweitzer AN, Sharpe AH, McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. [Review]. Immunol Rev 1998; 165:231-247.
36. Ding L, Linsley PS, Huang LY, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151(3):1224-1234.
37. Abbas AK, Sharpe AH. T-cell stimulation: an abundance of B7s [comment]. Nat Med 1999;5(12):1345-1346.
38. Aicher A, Hayden-Ledbetter M, Brady WA, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 2000; 164(9) 4689-11696
39. Chaul TA, McCully ML, Brintnell W, et al. Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat Med 2009; 15(6): 641-648.
40. McHugh RS, Shevach EM, McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002;168(12):5979-5983.